Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Coniel is a South Korean biotechnology company specializing in regenerative medicine and aesthetic medical devices. The company leverages its proprietary bio-convergence technology to develop high-performance biomaterials, including hyaluronic acid (HA) fillers and polynucleotide (PN) based products. Coniel's flagship product line, marketed under the "Coniel" brand, focuses on tissue restoration, skin rejuvenation, and anti-aging solutions for the global aesthetics market. Their research and development efforts are centered on advanced PDRN-based therapies for broader applications in tissue repair and wound healing. Headquartered in Seoul, the company aims to provide safe and effective aesthetic treatments through innovative cross-linking technologies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Coniel.